mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase InhibitorHeidi A. Lane, Terence O’Reilly|Clinical Cancer Research|2009Cited by 251
Validation of a Postfixation Tissue Storage and Transport Medium to Preserve Histopathology and Molecular Pathology Analyses (Total and Phosphoactivated Proteins, and FISH)Michael Stumm, Terence O’Reilly|American Journal of Clinical Pathology|2012Cited by 12